EP Patent

EP1951216A2 — Chemical compounds

Assigned to GlaxoSmithKline LLC · Expires 2008-08-06 · 18y expired

What this patent protects

The present invention discloses novel compounds with a variety of therapeutic uses. More particularly, the invention discloses novel symmetrical triphenyl compounds that are particularly useful for selective estrogen receptor modulation.

USPTO Abstract

The present invention discloses novel compounds with a variety of therapeutic uses. More particularly, the invention discloses novel symmetrical triphenyl compounds that are particularly useful for selective estrogen receptor modulation.

Drugs covered by this patent

Estrace (ESTRADIOL) · Pfizer

Patent Metadata

Patent number: EP1951216A2
Jurisdiction: EP
Classification: —
Expires: 2008-08-06
Drug substance claim: No
Drug product claim: No
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.